Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na⁺/H⁺ Exchanger Isoform 3

Jeffrey W. Jacobs,* Michael R. Leadbetter, Noah Bell, Samantha Koo-McCoy, Christopher W. Carreras, Limin He, Jill Kohler, Kenji Kozuka, Eric D. Labonté, Marc Navre, Andrew G. Spencer, and Dominique Charmot

Cite This: ACS Med. Chem. Lett. 2022, 13, 1043−1051

ABSTRACT: We present herein the design, synthesis, and optimization of gut-restricted inhibitors of Na⁺/H⁺ exchanger isoform 3 (NHE3). NHE3 is predominantly expressed in the kidney and gastrointestinal tract where it acts as the major absorptive sodium transporter. We desired minimally systemic agents that would block sodium absorption in the gastrointestinal tract but avoid exposure in the kidney. Starting with a relatively low-potency highly bioavailable hit compound (1), potent and minimally absorbed NHE3 inhibitors were designed, culminating with the discovery of tenapanor (28). Tenapanor has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritable bowel syndrome with constipation in adults.

KEYWORDS: Gastrointestinal tract, Intestinal targeting, Nonabsorbed drugs, Sodium−hydrogen exchanger, Tenapanor

Irritable bowel syndrome with constipation (IBS-C) is a highly prevalent medical condition that reduces quality of life and represents a substantial economic burden on the cost of healthcare.¹ IBS-C is characterized by altered bowel habits with abdominal pain, and its global prevalence is estimated to be anywhere from 5% to 20%.² There are multiple proposed theories and mechanisms regarding the pathophysiology of IBS; however, the exact etiology is still unclear.³ Treatment strategies are diverse and consist of osmotic or stimulant laxatives, motility agents, or secretagogues that act by stimulating intestinal fluid secretion, thereby accelerating gastrointestinal transit.⁴

Our treatment strategy focused on the selective inhibition of the epithelial brush border Na⁺/H⁺ exchanger isoform 3 (NHE3) within the gastrointestinal (GI) tract. NHE3 functions as part of neural NaCl absorption in both the intestine and in the renal proximal tubule of the kidney, where it accounts for the majority of the total Na⁺ absorbed.⁵ In animal studies, genetic knockouts confirm that NHE3 is the dominant NHE responsible for transepithelial Na⁺ absorption.⁶ We reasoned that the pharmacologic inhibition of NHE3 in the gut should result in an increase in the intestinal salt and fluid content, thus promoting GI motility, and would be a viable approach for the treatment of patients with constipation-related disorders. Restricting compound exposure to the GI tract is critical because inhibition in the kidney could result in a dysregulation of the Na⁺−water homeostasis and the potential perturbation of blood pressure.⁷ Our discovery strategy therefore focused on the design of gut-restricted inhibitors capable of inhibiting NHE3 on the brush border membrane of the GI tract while avoiding systemic exposure and the undesired inhibition of renal NHE3.

Initial work evaluated multiple pharmacophores with reported NHE3 inhibitory activity, including tetrahydroisoquinoline (THIQ) compound classes, as candidates for hit-to-lead optimization.⁸−¹¹ Compounds were tested for their NHE3 inhibition activity using a cell deacidiﬁcation assay, since the inhibition of Na⁺/H⁺ exchange blunts the passage of protons to the extracellular compartment. To this end, the dose-dependent inhibition of pH recovery in transfected opossum kidney cells overexpressing human (hu) and rat (r) NHE3 was assessed using a pH-sensitive dye. The pharmacokinetics (PK)
of the compounds were also determined. From this initial screen, THIQ compound 1 was selected for further study (Figure 1). While compound 1 possessed only moderate in vitro potency, it was essentially equipotent against human and rat NHE3 (pIC$_{50}$ = 6.2 hu and 6.6 r) and had a relatively low molecular weight (371 Da; Table 1). Substituted THIQ compounds such as 1 are also modular and relatively facile to synthesize. Challenges with the development of compound 1 included the absence of a pharmacodynamic (PD) effect in PK studies and high (98%) oral bioavailability in Sprague−Dawley rats, both significant challenges in an optimization effort focused on eliminating systemic exposure while greatly enhancing biological activity. Additional requirements for target compounds in this program also included GI stability and minimal metabolism by GI microflora, which could potentially release bioavailable active metabolites.

The THIQ core found in 1 is conveniently synthesized, as shown in Scheme 1. Commercially available 3-bromoacetophenone 1.0 is α-brominated with bromine in acetic acid to afford bromide 1.1, which is then used to alkylate 1-(2,4-dichlorophenyl)-N-methylmethanamine to afford intermediate 1.2. The reduction of 1.2 with sodium borohydride in methanol afforded amino alcohol 1.3, which underwent cyclodehydration via treatment with concentrated sulfuric acid to yield racemic tetrahydroisoquinoline 1.4. Compound 1.4 could either be used directly for derivatization via electrophilic aromatic substitution or Suzuki-type cross-couplings or converted to amine or carboxylate intermediates using established procedures.$^{12,13}$ Thus, intermediate 1.4 was sulfurized with benzyl mercaptan to give thioether 1.5, and oxidative chlorination with chlorine gas in acetic acid and water yielded sulfonyl chloride 1.6. Sulphonamide derivatives of

Figure 1. Structures of (A) compound 1 and (B) compound 28 (tenapanor).

Table 1. Structure−Activity Relationship (SAR) Suggesting a Solvent-Exposed Vector on the THIQ Pharmacophore

| Compound | R     | R versus S | pIC$_{50}$ (hu, r) | C$_{max}$/AUC (dose)* |
|----------|-------|------------|---------------------|-----------------------|
| 1        | O$_2$ | ±          | 6.2, 6.6            | 159/522 (11 mpk)      |
| 5        | O$_2$ | ±          | 6.5, 6.7            | NT                    |
| 6        | O$_2$ | ±          | 7.0, 7.0            | NT                    |
| 7        | O$_2$ | ±          | 5.8, 7.3            | NT                    |
| 8        | O$_2$ | ±          | 5.3, 7.2            | NT                    |
| 2        | O$_2$ | ±          | 7.3, 7.4            | NT                    |
| 3        | O$_2$ | R          | 5.6, 5.1            | NT                    |
| 4        | O$_2$ | S          | 7.6, 7.4            | 6/12 (1.5 mpk)        |
| 9        | O$_2$ | ±          | 6.3, 6.1            | 30/43 (2.0 mpk)       |
| 10       | O$_2$ | ±          | 5.3, NT             | NT                    |

*aAbbreviations and units used are as follows: C$_{max}$ (ng/mL); AUC (ng·hr/mL) (Sprague−Dawley rats), mpk, milligrams per kilogram; NT, not tested; and pIC$_{50}$ (hu, r), pIC$_{50}$ for the human/rat NHE3 proteins. For experimental details, see the Supporting Information.
The following reagents and conditions were used: (a) Br2 and AcOH at 60 °C; (b) 1-(2,4-dichlorophenyl)-N-methylmethanamine, dioxane, and Et3N at 25 °C; (c) NaBH4 and MeOH at 0 °C; (d) H2SO4 and CH2Cl2 from 0 °C to room temperature; (e) benzylthiol, K2CO3, Pd2(dba)3, and Xantphos at 140 °C; (f) N-chlorosuccinimide, AcOH, and H2O at room temperature; (g) RNH2, TEA, or DIPEA or an equivalent solvent; and (h) D-(+)-DBTA and EtOH/H2O.

sulfonyl chloride 1.6 were prepared from amines using either Schotten–Baumann conditions or organic bases to afford all compounds described herein, with the exception of the amides (2, 3, and 4). These amide derivatives were synthesized from intermediates prepared following the procedures described in Scheme 1; however, bromophenyl 1.1 was replaced with the corresponding protected amine to afford the aniline version of intermediate 1.4. Acetylation with activated carboxylic acids afforded the desired amides (experimental details are provided in the Supporting Information).

Hit optimization activities were initially focused on probing regions on compound 1 tolerant to chemical modification and determining where the activity could be improved. This work also aimed to locate regions that could tolerate the addition of functional groups predicted to reduce systemic availability. For example, the identification of solvent-exposed regions on the pharmacophore would allow the overall physical properties of the compound to be modulated by increasing polarity, increasing the number of hydrogen bond donors or acceptors, and increasing rotatable bonds, all functionality traditionally thought to hinder oral availability.

In our initial studies, derivatives of 1 were prepared using functionalities to increase the polarity (neutral hydrophilic, polar ionic, and constitutively charged), and the spacing between the THIQ core and the terminal functionality was systematically varied in an effort to determine a region of solvent exposure. As shown in Table 1, the meta (m) position of the THIQ core tolerated a diverse range of functionalities. Neutral hydrophilic (5) and ionic groups (6) were accommodated with minimal impact on the in vitro potency, as were functional groups constitutively charged at physiological pH (sulfonate (7) and phosphonate (8)). The carbohydrate derivative (2) was particularly potent (pIC50 = 7.3 hu and 7.2 r), suggesting that this region of the compound was not simply solvent exposed but also capable of forming productive binding interactions with NHE3.

To this point, all compounds made were prepared as racemic mixtures. Compound 2 was resolved via chiral supercritical fluid chromatography (SFC) to afford 3 and 4, which were later assigned R- and S-configurations, respectively. While 3 possessed weak in vitro activity (pIC50 = 5.6 hu and 5.1 r), 4 was potent (pIC50 = 7.6 hu and 7.4 r), had a promising (low) exposure in rat PK studies (maximum concentration (Cmax) of 6 ng/mL and area under the curve (AUC) 12 ng·hr/mL at 1.5 mg/kg), and was active (10 mg/kg dose) in a rat PD assay, consistent with luminal NHE3 inhibition (Supplementary Figure S1). The PD assay at this point in the program consisted of an analysis of the intestinal sodium content within the lumen of the cecum or the colon of sacrificed rats (see Supporting Information); changes in urinary sodium were not yet detected. The finding of in vitro potency pIC50 > 7, reduced systemic exposure, and a PD response in a relevant animal model satisfied our “hit” criteria.
Insights from 5, a simple ether analog with a modestly increased potency, suggested that the oxygens in 2 and 4 may serve as H-bond acceptors rather than donors. Therefore, short polyethylene glycols (PEGs) were considered to determine whether activity similar to that of the carbohydrate derivatives could be maintained without the added stereocheristry of a polyol. Thus, 9 was prepared, and it had both a reasonable pIC_{50} (6.3 hu and 6.1 r) and a similarly low bioavailability (C_{max} = 30 ng/mL and AUC = 43 ng·hr/mL at 2.6 mg/kg; Table 1). The aminopolyethylene glycol of 9 was also a convenient vector for exploring the limits of chemical space in this region of the molecule. Although unconventional, dimerization via the aminopolyethylene glycol was investigated to determine the maximum reduction in systemic exposure that could result from such analogs, which have a relatively high molecular weight, possess a significant number of H-bond acceptors, have a high topological polar surface area, and possess a large number of rotatable bonds. The first dimer, 10, was prepared by directly sulfonylating 9 with sulfonyl chloride 1.6 and was essentially inactive (pIC_{50} < 5.3 hu; Table 1). The additional THIQ moiety was likely making unproductive contact with NHE3, so significantly longer dimers were designed. Tartaric acid was used as a “core” to dimerize two 9 molecules; 9 was chosen because its polyol backbone bore an architecture similar to that of 2 and 4. The resulting compound, 11, represented a breakthrough in the program (Table 2). While in vitro potency (pIC_{50} = 7.1 hu and 7.6 r) was similar to that of 4 (with a pure enantiomer of 11 expected to be more potent still), systemic exposure was significantly attenuated (C_{max} = 6 ng/mL and AUC = 6 ng·hr/mL at 9.4 mg/kg). Critically, a robust PD response was observed in rats (10 mg/kg dose) in the form of a pronounced increase (56%) in stool water (Table 2). This observation is consistent with the phenotype of NHE3-null mice15 and the activity of another intestinal NHE3 inhibitor16 published after our initial reports.17−20 Since wet feces made accurate stool collection in a metabolic cage impractical, the analysis of urinary Na⁺ became a primary PD biomarker, since blocking Na⁺ absorption in the GI tract would result in the reduced fractional excretion of Na⁺ in the urine (see the Supporting Information). Compound 11 robustly reduced the excretion of Na⁺ in the urine in a dose-dependent manner (Figure 2), consistent with blockade of intestinal NHE3. In polarized Madin−Darby canine kidney (MDCK) cells, the bidirectional apparent permeability (P_{app}) of 11 was <0.2 × 10^{-6} cm/s, indicating poor absorption across the epithelium. In contrast, the P_{app} of 1 was ≥10 × 10^{-6} cm/s, indicating extensive absorption. These results were consistent with the plasma C_{max} values of these compounds after oral administration in rats (Tables 1 and 2). The combination of in vitro potency,

### Table 2. Effects of Linker Length, Regiochemistry, And Stereochemistry on SAR of THIQ Dimers

| compound | R versus S | m/p | n | pIC_{50} (hu, r) | C_{max}/AUC (dose)^b | PD (3 mpk) |
|----------|------------|-----|---|-----------------|----------------------|------------|
| 11       | ±, ±       | m   | 3 | 7.1, 7.6        | 6/6 (9.4 mpk)        | fecal form^c |
| 12       | ±, ±       | m   | 2 | 7.2, 6.9        | <1/<4 (9 mpk)        | fecal water^d |
| 13       | ±, ±       | m   | 1 | 6.5, 5.8        | NT                   | urine Na^e  |
| 14       | ±, ±       | m   | 0 | 6.0, 6.3        | <4/<10 (11 mpk)      | NT         |
| 15       | ±, ±       | p   | 3 | 6.8, 7.2        | <5/<19 (10 mpk)      | NT         |
| 16       | ±, ±       | p   | 2 | 8.4, 7.0        | NT                   | NT         |
| 17       | S, S       | m   | 3 | 8.9 (r)         | NT                   | NT         |
| 18       | S, R       | m   | 3 | 6.7 (r)         | NT                   | NT         |
| 19       | R, R       | m   | 3 | <4.5 (r)        | NT                   | NT         |

^aAbbreviations used are as follows: m, meta; mpk, milligrams per kilogram; NT, not tested; p, para; and pIC_{50} (hu, r), pIC_{50} for the human/rat NHE3 proteins. For experimental details, see the Supporting Information. ^bC_{max} (ng/mL) and AUC (ng·hr/mL). ^cStool form scale (1 = “hard pellet” and 5 = “watery”). ^dPercent water by weight. ^ePercent control.

Figure 2. Activity of the THIQ dimer 11 in an in vivo pharmacodynamic urinary sodium excretion assay in rats. ****p < 0.0001 versus the vehicle. Data shown are the mean (±SEM) reduction in urine sodium (mg) 16 h after the oral administration of compound 11 at 3, 10, and 30 mg/kg (n = 6 per group). A one-way ANOVA test with Dunnett’s multiple comparison test was used to determine the statistical significance.

https://doi.org/10.1021/acsmedchemlett.2c00037
ACS Med. Chem. Lett. 2022, 13, 1043−1051
favorable (minimally systemic) PK properties, and a robust PD dose--response satisfied our “lead” criteria, and the optimization of 11 became a focus of the program.

The initial optimization of 11 explored the refinement of the linker length and the regiochemistry of the sulfonamide (meta versus para; Table 2). A methodology had not been established for preparing sulfonyl chloride intermediate 1.6 (Scheme 1) in an enantiomerically pure form (intermediate 1.9; Scheme 1), so compounds were prepared as diastereomeric mixtures. While the tartaric acid core was maintained, meta sulfonamide analogs were prepared with PEG lengths of 3 (11), 2 (12), 1 (13), and 0 (1,2-diaminoethane; 14) ethylene glycol units, which revealed minimal spacing requirements. Compounds 11 (PEG-3) and 12 (PEG-2) were essentially equipotent both in vitro (pIC50 = 6.9–7.6 r) and in the PD response (urinary Na+ excretion reduced to 24–33% that of the vehicle controls; 3 mg/kg), while 13 (PEG-1) and 14 (PEG-0) were approximately 1–1.5 orders of magnitude less potent in vitro (Table 2). Analysis of the para-sulfonamide regiochemistry (15 (PEG-3) and 16 (PEG-2)) suggested that the PEG-2 length was preferred in this framework (16, pIC50 = 8.4 hu and 7.0 r; urinary Na+ was 11% that of the control). All tested compounds in this series had very low exposure in rats (< 10 ng/mL and AUC < 20 ng·hr/mL at 10 mg/kg). Note that, due to the robust PD response of 11, the screening dose for PD studies was reduced to 3 mg/kg, while the PK dose was maintained at 10 mg/kg, with plasma concentrations approaching the detection limits (typically 0.5–5 ng/mL) of our routine PK screening methodology.

Stereocchemical preferences within the chemotype 11 were then reconfirmed (Table 2). PEG intermediate 9 was purified by chiral SFC into what were later assigned as the R- and S- enantiomers via single-crystal X-ray analysis of the d- (+)- dibenzoyl tartaric acid (DBTA) salt of intermediate 1.7 (see the Supporting Information). These enantiomers were used to prepare diastereomers 17 (S,S), 18 (S,R), and 19 (R,R). Note that 17 and 18 were prepared using L- (+)-tartaric acid, while 19 was prepared from racemic tartaric acid. The S-configuration was strongly preferred, with nearly two orders of magnitude separating the in vitro potency of 17 (S,S) pIC50 = 8.9 r from that of 18 (S,R; pIC50 = 6.7 r), which had an activity similar to that of monomer 9 (Table 2). Compound 19 was inactive (R,R; pIC50 < 5.0 r). Modulating the stereochemistry in this fashion preserved the identical molecular mass and nearly identical functionality but changed the bioactive conformation of the THIQ pharmacophore. This had a dramatic impact on the in vitro potency, suggesting a synergistic binding mode for the dimeric pharmacophore.

Although the chemical series exemplified by 11 satisfied most of our lead criteria, the recovery of the intact parent compound from rat fecal samples was variable (57–97% within 16 h at 10 mg/kg) and hydrolysis products were observed (especially at the tartrate “core”). The hydrolytic instability of the amide at this position was also observed during some synthetic conditions, perhaps due to anchimeric assistance of the vicinal hydroxyl groups. As these fragments presented a risk of further optimization was performed within the linker and core region.

### Table 3. SARs of THIQ Dimers with Different Core Regions

| Compound | R versus S | m/p | n | Core            | pIC50 (hu, r) | AUC (ng·hr/mL) | PD (3 mpk) |
|----------|------------|-----|---|-----------------|---------------|----------------|------------|
| 36       | +/-        | m   | 3 | Core            | 7.3, 7.6      | AUC < 12 (7.2 mpk) | 53%        |
| 20       | +/-        | m   | 2 | Core            | < 5.5, 5.2    | < 5.5 < 5.2 (23 mpk) | 58%        |
| 37       | +/-        | p   | 3 | Core            | 7.4, 7.9      | < 5.5 < 5.5 (23 mpk) | 58%        |
| 21       | +/-        | p   | 2 | Core            | < 5.5, 8.4    | < 5.5 < 8.4 (23 mpk) | 45%        |
| 38       | +/-        | m   | 3 | Core            | 6.7, 7.0      | < 5.5 < 7.0 (23 mpk) | 50%        |
| 22       | +/-        | m   | 2 | Core            | 5.7, < 5.0    | < 5.5 < 7.0 (23 mpk) | 50%        |
| 35       | +/-        | p   | 3 | Core            | 7.2, 7.1      | < 5.5 < 5.5 (23 mpk) | 50%        |
| 23       | +/-        | p   | 2 | Core            | < 5.5, < 5.5  | < 5.5 < 5.5 (23 mpk) | 50%        |
| 39       | +/-        | m   | 3 | Core            | NT, 5.2       | NT             | 54%        |
| 27       | +/-        | m   | 2 | Core            | NT, 8.1       | NT             | 54%        |
| 40       | +/-        | p   | 3 | Core            | NT, NT        | NT             | 54%        |
| 41       | +/-        | p   | 2 | Core            | NT, NT        | NT             | 54%        |
| 25       | +/-        | m   | 3 | Core            | 7.4, 7.9      | 3              | 57%        |
| 29       | +/-        | m   | 2 | Core            | NT, 8.5       | 4.5            | 57%        |
| 42       | +/-        | p   | 3 | Core            | NT, NT        | NT             | 57%        |
| 43       | +/-        | p   | 2 | Core            | NT, NT        | 3              | 57%        |
| 44       | +/-        | m   | 3 | Core            | NT, NT        | < 2 < 8 (28 mpk) | 57%        |
| 33       | +/-        | p   | 2 | Core            | 7.2, 7.4      | 3              | 57%        |
| 45       | +/-        | m   | 3 | Core            | NT, NT        | NT             | 57%        |
| 31       | +/-        | p   | 2 | Core            | 7.5, 7.6      | 2.5            | 57%        |
| 46       | +/-        | m   | 3 | Core            | NT, NT        | 3              | 57%        |

**Note:**
- C_{max} (ng/mL) and AUC (ng·hr/mL).
- Stool form scale (1 = “normal” and 5 = “watery”).
- Percent water by weight.
- Percent control.

**Abbreviations used are as follows:** m, meta; mpk, milligrams per kilogram; NT, not tested; p, para; and pIC50 (hu, r), pIC50 for human/rat NHE3.
The pharmacophore was optimized by systematically probing combinations of the sulfonamide regiochemistry, the linker length, and the central core. Variations of the sulfonamide regiochemistry were meta versus para; the para-sulfonyl chloride analog of compound 1.6 was analogously prepared from 4-bromoacetophenone following the procedures in Scheme 1. The linker length was PEG-2 versus PEG-3, and the central core was amide versus urea connection chemistry; aliphatic, aromatic, ether, and amine cores are shown in Table 3. Each compound was prepared as a mixture of diastereomers.

Compound evaluation included in vitro potency, exposure (primarily C\text{max} since AUC was typically not calculable due to insufficient quantifiable plasma concentrations), PD effect (percent reduction in urinary Na\textsuperscript{+}), fecal excretion (percent of the dose recovered as the intact parent compound), and pH/solubility profile. Solubility was typically high in simulated

Table 4. Summary of Activity for the Six Preferred THIQ Dimers and the Final Assessment Criteria\textsuperscript{c}

| Compound | m/p | n | "Core" | Stool water dose-response | Increase in stool water | Stool recovery\textsuperscript{a} | pIC\textsubscript{50} (hu, r) | C\textsubscript{max} at 30 mpk\textsuperscript{b} |
|----------|-----|---|--------|--------------------------|------------------------|-----------------|-----------------|-----------------|
| Assessment criteria | — | — | — | Yes | 10% increase from control | >70% | - | low |
| 24 | m | 3 | | | | | 96 ± 14% | No metabolites detected | 8.7, 8.2 | <15 ng/mL | No metabolites detected |
| 26 | m | 2 | | | | | 93 ± 16% | No metabolites detected | 8.8, 8.6 | <2 ng/mL | No metabolites detected |
| 28 | m | 2 | | | | | 92 ± 2% | 2 metabolites detected | 9.3, 7.8 | <3 ng/mL | No metabolites detected |
| 30 | p | 2 | | | | | 117 ± 6% | No metabolites detected | 8.1, 8.0 | <2 ng/mL | No metabolites detected |
| 32 | p | 2 | | | | | 46 ± 8% | No metabolites detected | 8.8, 8.0 | <2 ng/mL | No metabolites detected |
| 34 | p | 3 | | | | | 82 ± 20% | 3 metabolites detected | 8.1, 7.9 | <5 ng/mL | No metabolites detected |

\textsuperscript{a}Data are the mean ± standard deviation (n = 30, 10 replicates from three rats for 26, 28, and 32; n = 9, three replicates from three rats for 24, 30, and 34. Stool recovery could be greater than 100% due to sample inhomogeneity. \textsuperscript{b}C\textsubscript{max} (ng/mL). \textsuperscript{c}Abbreviations used are as follows: m, meta; mpk, milligrams per kilogram; p, para; and pIC\textsubscript{50} (hu, r), pIC\textsubscript{50} for the human/rat NHE3 proteins. For experimental details, see the Supporting Information.

Figure 3. Dose response of urinary sodium excretion for the six THIQ dimer NHE3 inhibitor compounds in rats. Data shown are the mean (±SEM) reduction in urine sodium (mg) 16 h after the oral administration of each compound at 0.1, 0.3, 1.0, and 3.0 mg/kg (n = 6 per group). A one-way ANOVA test with Dunnett’s multiple comparison test was used to determine the statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001), and ns stands for not significant.

The pharmacophore was optimized by systematically probing combinations of the sulfonamide regiochemistry, the linker length, and the central core. Variations of the sulfonamide regiochemistry were meta versus para; the para-sulfonyl chloride analog of compound 1.6 was analogously prepared from 4-bromoacetophenone following the procedures in Scheme 1. The linker length was PEG-2 versus PEG-3, and the central core was amide versus urea connection chemistry; aliphatic, aromatic, ether, and amine cores are shown in Table 3. Each compound was prepared as a mixture of diastereomers. Compound evaluation included in vitro potency, exposure (primarily C\textsubscript{max} since AUC was typically not calculable due to insufficient quantifiable plasma concentrations), PD effect (percent reduction in urinary Na\textsuperscript{+}), fecal excretion (percent of the dose recovered as the intact parent compound), and pH/solubility profile. Solubility was typically high in simulated
gastric fluid (>5 mg/mL; data not shown), consistent with the presence of two tertiary amines in each analog. When measured, systemic exposure throughout the series was very low, even when the dose was increased to 20 mg/kg (e.g., compound 20, $C_{\text{max}} < 2$ ng/mL at a 22 mg/kg dose, and compound 21, $C_{\text{max}} < 3$ ng/mL at a 23 mg/kg dose). The in vitro potency ($pIC_{50}$) of these diastereomeric mixtures was generally $>7$, which was expected to improve to $\sim 8$ when the compounds were prepared in the stereochemically pure form. Analogs with a shorter PEG length and a smaller core (22 and 23) had poor in vitro activity ($pIC_{50} \leq 5.7$), which was consistent with prior SARs showing the dependence of the optimal activity on the appropriate spacing between the two THIQ pharmacophores.

Six compounds that appeared to satisfy preliminary development candidate criteria were prepared in the stereochemically pure form, either by chiral SFC or via intermediate 1.9, and carefully evaluated (Table 4). These included compounds 24 ($S,S$-diastereomer of 25), 26 ($S,S$-diastereomer of 27), 28 ($S,S$-diastereomer of 29), 30 ($S,S$-diastereomer of 31), 32 ($S,S$-diastereomer of 33), and 34 ($S,S$-diastereomer of 35). These compounds also represented a cross-section of sulfonamide regiochemistry, linker length, and core motifs. In addition to established in vitro and in vivo tests, compound evaluation activities were expanded to include the PD dose—response (urine $Na^+$ at 0.1–3.0 mg/kg), the value of $C_{\text{max}}$ at a high dose (30 mg/kg), the increase in fecal water content (≥10% increase over control animals), fecal recovery of the intact parent (≥70%), human ether-a-go-go-related gene (hERG) inhibition (<50% at 10 μM), and Ames (negative).

Both hERG inhibition and Ames were negative for all six compounds. As shown in Table 4, the stool water content increased by >10% for all compounds except 24. Fecal recovery of the intact compound was >70% the administered dose for all analogs except 32 (46% ± 8%). $pIC_{50}$ values were quite potent for these pure diastereomers ($pIC_{50} = 8.1$–9.3 hu and 7.9–8.2 r), and exposure ($C_{\text{max}}$(rat) = 30 mg/kg) was below the limit of detection for all compounds ($C_{\text{max}} < 5$ mg/mL for most analogs). All compounds had a robust PD dose response, and the activity was clearly titratable (Figure 3). In some instances, there appeared to be an increase in the fractional excretion of $Na^+$ in urine at higher doses of compound 32 and 28 at 3.0 mg/kg, but this is likely due to the incidental diversion of sodium-rich loose stools into the urinary collection tube in the metabolic cages at high compound doses. Compound 24 did not demonstrate a satisfactory pharmacodynamic dose—response effect on stool water, while 32 showed unsatisfactory GI stability (fecal recovery of 46% ± 8%). Compounds 30 and 34 had comparatively lower in vitro activity against human NHE3 ($pIC_{50} = 8.1$) compared to the other analogs. The totality of data supported compounds 28 and 26 as potential development candidates.

To further characterize these candidates, a seven day repeat-dose exploratory (i.e., non-good laboratory practice (non-GLP)) rat toxicity study was carried out. Gross and microscopic pathologies were within normal limits for all compounds, and no biologically significant abnormal clinical pathology was observed (i.e., alanine aminotransferase/aspartate aminotransferase >3X the upper limit of normal; data not shown, see the Supporting Information). Dehydration was observed due to the exaggerated PD response (i.e., diarrhea) at the studied dose (30 mg/kg). Compound 26 was ultimately rejected because an examination of its inhibition in the cell assay showed it never reached 100% (data not shown) and the potential risk of reactive quinone imine formation due to its diaminobenzene core should a fragment become systemic. 21 Key compound 28 (tenapanor) satisfied all development candidate criteria and was advanced into clinical development.

In clinical trials, tenapanor (28) softened stool consistency in a dose-dependent manner and increased stool frequency and weight versus the placebo. 22 Importantly, tenapanor plasma concentrations were below the quantification limit (0.5 ng/mL) in >95% of all plasma samples analyzed, demonstrating the successful achievement of the goal of minimal systemic absorption in humans. Tenapanor (28) was approved for the treatment of adult patients with IBS-C by the U.S. Food and Drug Administration (FDA) in September of 2019. 23–25 During clinical development, it was also observed that tenapanor (28) lowered serum phosphorus levels in dialysis patients with hyperphosphatemia, a major comorbidity in this patient population, by preventing the intestinal absorption of phosphate. 22 In mechanistic studies, the on-target inhibition of NHE3 causes a decrease in the intracellular pH (pH i) of intestinal epithelial cells. This decrease in pH is thought to modulate the tight junctions between the epithelial cells, resulting in an increase in the transepithelial electrical resistance that restricts the paracellular permeability of phosphate, the major pathway for intestinal phosphate absorption. 26,27 The primary and most secondary end points were met in three pivotal clinical trials of tenapanor for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis. 28,29

In summary, tenapanor (28) is a novel, potent, and minimally absorbed inhibitor of intestinal NHE3 that functions in the gastrointestinal tract to block the absorption of dietary sodium and phosphate. Systematic optimization of the regioisomer and spatial relationships within this series resulted in a potent and minimally absorbed chemotype suitable for clinical development. Data from multiple completed clinical trials led to tenapanor being approved by the U.S. FDA for the treatment of adult patients with IBS-C.

### ASSOCIATED CONTENT

![Supporting Information](https://pubs.acs.org/acsmedchemlett.2c00037)

Water content from the cecum and the colon; experimental procedures, including materials and methods; and chemical characterization of compounds (PDF)

### AUTHOR INFORMATION

#### Corresponding Author

**Jeffrey W. Jacobs** — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Goldfinch Bio, 215 First St., Cambridge, Massachusetts 02142, United States; Email: jjacobs@goldfinchbio.com

#### Authors

**Michael R. Leadbetter** — Ardelyx, Inc., Waltham, Massachusetts 02451, United States
Noah Bell — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Notac Pharma, 405 South Motor Avenue, Azusa, California 91702, United States
Samantha Koo-McCoy — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Syncopation Life Sciences, 1900 Alameda de Las Pulgas, San Mateo, California 94403, United States
Christopher W. Carreras — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: ProLynx, Inc., 455 Mission Bay Boulevard South, San Francisco, California 94158, United States
Limin He — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: CymaBay Therapeutics, 7575 Gateway Boulevard, Suite 110, Newark, California 94560, United States
Jill Kohler — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: ProLynx, Inc., 7707 Gateway Boulevard, Suite 140, Newark, California 94560, United States
Kenji Kozuka — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Visterra, Inc., 275 2nd Avenue, Waltham, Massachusetts 02451, United States
Eric D. Labonté — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Recursion Pharma, 41 South Rio Grande Street, Salt Lake City, Utah 84101, United States
Marc Navre — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Wembersly Scientific, Inc., 2708 Wemberly Drive, Belmont, California 94002, United States
Andrew G. Spencer — Ardelyx, Inc., Waltham, Massachusetts 02451, United States; Present Address: Empirico Inc., 11682 El Camino Real, San Diego, California 92130, United States
Dominique Charmot — Ardelyx, Inc., Waltham, Massachusetts 02451, United States

Complete contact information is available at: https://pubs.acs.org/10.1021/acsmedchemlett.2c00037

Author Contributions
The manuscript was written by J.W.J. with assistance from Oxford Pharmagenesis and Ashfield MedComms, an Ashfield Health company. Chemistry and compound design was contributed by M.R.L., N.B., and J.W.J. In vitro assay development and execution were performed by C.W.C. and S.K.M. In vivo study design and execution were performed by M.N., E.D.L., K.K., L.H., A.G.S., D.C., and J.W.J. M.R.L., C.W.C., K.K., E.D.L., M.N., A.G.S., D.C., and J.W.J. analyzed or interpreted data. D.C. and J.W.J. conceived of and initiated the project. All authors contributed to manuscript review and revision, approved the final draft for submission, and are accountable for accuracy and integrity of any part of the work.

Funding
This work was funded by Ardelyx, Inc.

Notes
The authors declare the following competing financial interest(s): J.W.J., M.R.L., L.H., K.K., M.N., and A.G.S. were employed by and own stock in Ardelyx, Inc. N.B., S.K.M., C.W.C., J.K., E.D.L., and D.C. were employed by Ardelyx, Inc.

ACKNOWLEDGMENTS
The authors thank Pharmaron, Beijing, China, for assistance with compound preparation.

ABBREVIATIONS
ANOVA, analysis of variance; AUC, area under the curve; CKD, chronic kidney disease; C_{max} maximum concentration; DBTA, dibenzoyltaurinic acid; FDA, U.S. Food and Drug Administration; GI, gastrointestinal; hERG, human ether-a-go-go-related gene; hA, human; IBS-C, irritable bowel syndrome with constipation; m, meta; MDCK, Madin–Darby canine kidney; mpk, milligrams per kilogram; NHE3, Na+/H+ exchanger isoform 3; non-GLP, non-good laboratory practice; NT, not tested; p, para; Papp, apparent permeability; PD, pharmacodynamic; PEG, polyethylene glycol; pH, intracellular pH; PK, pharmacokinetic; r, rat; SARP, structure–activity relationship; SEM, standard error of the mean; SFC, supercritical fluid chromatography; THIQ, tetrahydroisoquinoline

REFERENCES
(1) Luthra, P.; Camilleri, M.; Burr, N. E.; Quigley, E. M. M.; Black, C. J.; Ford, A. C. Efficacy of Drugs in Chronic Idiopathic Constipation: A Systematic Review and Network Meta-Analysis. Lancet Gastroenterol Hepatol 2019, 4 (11), 831–844.
(2) Rao, S.; Weber, H. C. New Treatment Targets for the Management of Irritable Bowel Syndrome. Curr. Opin. Endocrinol Diabetes Obes 2014, 21 (1), 9–14.
(3) Munjal, A.; Dedania, B.; Cash, B. Update on Pharmacotherapy for Irritable Bowel Syndrome. Curr. Gastroenterol Rep 2019, 21 (6), 25.
(4) Donowitz, M.; Mohan, S.; Zhu, C. X.; Chen, T. E.; Lin, R.; Cha, B.; Zachos, N. C.; Murtazina, R.; Sarker, R.; Li, X. NHE3 Regulatory Complexes. J. Exp. Biol. 2009, 212 (11), 1638–1646.
(5) Donowitz, M.; Li, X. Regulatory Binding Partners and Complexes of NHE3. Physiol Rev. 2007, 87 (3), 825–72.
(6) Gavenis, L. R.; Stien, X.; Shull, G. E.; Schultheis, P. J.; Woo, A. L.; Walker, N. M.; Clarke, L. L. Intestinal NaCl Transport in NHE2 and NHE3 Knockout Mice. Am. J. Physiol Gastrointest Liver Physiol 2002, 282 (5), S776–84.
(7) Fenton, R. A.; Poulson, S. B.; de la Mora Chavez, S.; Soleimani, M.; Dominguez Rieg, J. A.; Rieg, T. Renal Tubular NHE3 Is Required in the Maintenance of Water and Sodium Chloride Homeostasis. Kidney Int. 2017, 92 (2), 397–414.
(8) Schwark, J. R.; Jansen, H. W.; Lang, H. J.; Krick, W.; Burckhardt, G.; Hropot, M.; S3226, a Novel Inhibitor of Na+/H+ Exchanger Subtype 3 in Various Cell Types. Pflugers Arch 1998, 436 (5), 797–800.
(9) Gericke, R. 4-Arylquinazolines and the Use Thereof as NHEJ-3 Inhibitors. US 2005020612 A1, 2005.
(10) Hofmeister, A.; Heinelt, U.; Lang, H.-J.; Bleich, M.; Wirth, K.; Gehle, M. Substituted 4-Phenyltetrahydroisoquinolinium, Process for Their Preparation, Their Use as a Medicament, and Medicament Containing Them. US 6911453 B2, 2005.
(11) Hofmeister, A.; Hropot, M.; Heinelt, U.; Bleich, M.; Lang, H. J. Substituted Cinnamic Acid Guanides, Process for Their Preparation, Their Use as a Medicament, and Medicament Comprising Them. US 6399824 B1, 2002.
(12) Bifis, A.; Centomo, P.; Del Zotto, A.; Zecca, M. Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review. Chem. Rev. 2018, 118 (4), 2249–2295.
(13) Ruiz-Castillo, P.; Buchwald, S. L. Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions. Chem. Rev. 2016, 116 (19), 12564–12649.
(14) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral
Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45 (12), 2615–2623.
(15) Schultheis, P. J.; Clarke, L. L.; Meneton, P.; Miller, M. L.; Soleimani, M.; Gaweins, L. R.; Riddle, T. M.; Duffy, J. J.; Doetschman, T.; Wang, T.; Giebish, G.; Aronson, P. S.; Lorenz, J. N.; Shull, G. E. Renal and Intestinal Absorptive Defects in Mice Lacking the Nhe3 Na+/H+ Exchanger. Nat. Genet. 1998, 19 (3), 282–5.
(16) Linz, D.; Wirth, K.; Linz, W.; Heuer, H. O.; Frick, W.; Hofmeister, A.; Heinelt, U.; Arndt, P.; Schwahn, U.; Bohm, M.; Ruetten, H. Antihypertensive and Laxative Effects by Pharmacological Inhibition of Sodium-Proton-Exchanger Subtype 3-Mediated Sodium Absorption in the Gut. Hypertension 2012, 60 (6), 1560–7.
(17) Spencer, A. G.; Jacobs, J. W.; Leadbetter, M. R.; Carreras, C. W.; Du, X.; Bell, N.; Koo-McCoy, S.; Kohler, J. N.; Labonte, E.; Rosenbaum, D. P.; Navre, M.; Charmot, D. Rdx5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC Absorption and Phosphate Homeostasis. Gastroenterology 2011, 140 (5), S99–105.
(18) Spencer, A. G.; Navre, M.; Plato, C. F.; Joly, K. M.; Labonte, E. D.; Jacobs, J. W.; Charmot, D. Rdx5791, a Non-Systemic Nhe3 Inhibitor, Normalizes Blood Pressure and Reduces Salt-Induced Organ Damage in Uremic Rats. J. Am. Soc. Nephrol. 2011, 22, 103A.
(19) Rosenbaum, D.; Jacobs, J. W.; Spencer, A. G.; Raab, M.; Charmot, D. Rdx5791, a Non-Systemic Nhe3 Inhibitor for the Treatment of Fluid and Sodium Overload, Shifts Sodium Excretion from Urine to Feces in Healthy Subjects. Nephrol. Dial. Transplant. 2012, 27 (S2), FP177.
(20) Rosenbaum, D. P.; Spencer, A. G.; Jacobs, J. W.; Charmot, D. The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers. Am. J. Gastroenterol. 2011, 106, S504.
(21) Monks, T. J.; Jones, D. C. The Metabolism and Toxicity of Quinones, Quinonimines, Quinone Methides, and Quinone-Thiethers. Curr. Drug Metab. 2002, 3 (4), 425–38.
(22) Rosenbaum, D. P.; Yan, A.; Jacobs, J. W. Pharmacodynamics, Safety, and Tolerability of the Nhe3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers. Clin Drug Invest 2018, 38 (4), 341–351.
(23) Chey, W. D.; Lembo, A. J.; Rosenbaum, D. P. Tenapanor Treatment of Patients with Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. Am. J. Gastroenterol 2017, 112 (5), 763–774.
(24) Chey, W. D.; Lembo, A. J.; Rosenbaum, D. P. Efficacy of Tenapanor in Treating Patients with Irritable Bowel Syndrome with Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3mpo1). Am. J. Gastroenterol 2020, 115 (2), 281–293.
(25) Chey, W. D.; Lembo, A.; Phillips, J. A.; Rosenbaum, D. P. 1020 Efficacy and Safety of Tenapanor in Patients with Constipation Predominant Irritable Bowel Syndrome: A 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial. Gastroenterology 2015, 148 (4), S191–S192.
(26) King, A. J.; Siegel, M.; He, Y.; Nie, B.; Wang, J.; Koo-McCoy, S.; Minassian, N. A.; Jafari, Q.; Pan, D.; Kohler, J.; Kumaraswamy, P.; Kozuka, K.; Lewis, J. G.; Dragoli, D.; Rosenbaum, D. P.; O’Neill, D.; Plain, A.; Greasley, P. J.; Jönsson-Rylander, A. C.; Karlsson, D.; Behrendt, M.; Strömstedt, M.; Ryden-Bergsten, T.; Knöpfel, T.; Pastor Arroyo, E. M.; Hernando, N.; Marks, J.; Donowitz, M.; Wagner, C. A.; Alexander, R. T.; Caldwell, J. S. Inhibition of Sodium/Hydrogen Exchanger 3 in the Gastrointestinal Tract by Tenapanor Reduces Paracellular Phosphate Permeability. Sci. Transl Med. 2018, 10 (456), eaam6474.
(27) Marks, J. The Role of Slc34a2 in Intestinal Phosphate Absorption and Phosphate Homeostasis. Pflugers Arch 2019, 471 (1), 165–173.
(28) Block, G. A.; Rosenbaum, D. P.; Leonsson-Zachrisson, M.; Astrand, M.; Johansson, S.; Knutsson, M.; Langkilde, A. M.; Chertow, G. M. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. J. Am. Soc. Nephrol 2017, 28 (6), 1933–1942.
(29) Block, G. A.; Rosenbaum, D. P.; Yan, A.; Chertow, G. M. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J. Am. Soc. Nephrol 2019, 30 (4), 641–652.